A Phase 3 interventional study of Olaparib and Physician's choice chemotherapy in Breast Cancer Metastatic, BRCA 1 Gene Mutation and BRCA 2 Gene Mutation, sponsored by AstraZeneca. Completed at 171 sites in 19 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.
Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 3, and was the 9th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Okayama University · Sites in Japan
Ages 18+
Mary D Chamberlin · Sites in United States
Ages 18+ · Women only
German Cancer Research Center · Sites in Germany
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 27 · Phase 3 6 · Phase 4 3
First in 2007; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 51 interventional studies. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 39th largest by enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2014, is one of 46 in phase 3, and was the 103rd registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
4 of the studies testing olaparib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03740893Institute of Cancer Research, United KingdomPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer | 2026-12 |
| NCT03594396Seoul National University HospitalWindow of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer | 2026-12-31 |
| NCT04683679Memorial Sloan Kettering Cancer CenterA Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies testing olaparib in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib tablet 300mg bd po
Drug: Olaparib
Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
Drug: Physician's choice chemotherapy
Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
Investigators will declare one of the following regimens: * Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days * Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days * Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Time to Second Progression or Death (PFS2)
Time from randomisation to the earliest of the progression event subsequent to the first objective radiological progression, or death. Second progression may involve any of; objective radiological or symptomatic progression or death. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Symptomatic progression is assessed by investigators based on clinical examination.
Time frame: Second progression status reviewed every 8 weeks following the first objective radiological progression as per investigator assessment. Assessed up to a maximum of 30 months.
Overall Survival (OS)
Time from randomisation until death due to any cause.
Time frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 30 months.
Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
Number of responders according to blinded independent central review (BICR) assessment. Per Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR.
Time frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)
Change from baseline in global health status/quality of life (QoL) score assessed using a mixed model for repeated measures (MMRM) analysis, including all post-baseline global health status/QoL scores up to the latest scheduled visit where at least 20 patients on each treatment arm have a score. Global health status/QoL score is on a scale from 0 to 100. A higher score represents an improved health status/QoL.
Time frame: EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm
Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Assessed in patients with a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).
Time frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Overall Survival (OS) at Final OS
Time from randomisation until death due to any cause.
Time frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 40 months.
Overall Survival (OS) at Extended OS
Time from randomisation until death due to any cause.
Time frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
Time to First Subsequent Cancer Therapy or Death (TFST)
Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.
Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
Time to Second Subsequent Cancer Therapy or Death (TSST)
Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.
Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
Time to First Subsequent Cancer Therapy or Death (TFST) at Extended OS
Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.
Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS
Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.
Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
The first patient was enrolled on 27 March 2014 and the last patient on 30 October 2015. Patients were randomized at 125 centres across 19 countries in North America, South America, Europe and Asia.
| Milestone | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Started | 205 | 97 |
| Completed | 36 | 17 |
| Not completed | 169 | 80 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Death | 159 | 73 |
| Withdrew: Withdrawn due to site closure | 1 | 0 |
Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) | 7.0 (5.7 to 8.3) | 4.2 (2.8 to 4.3) |
Time from randomisation to the earliest of the progression event subsequent to the first objective radiological progression, or death. Second progression may involve any of; objective radiological or symptomatic progression or death. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Symptomatic progression is assessed by investigators based on clinical examination.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Time to Second Progression or Death (PFS2) | 13.2 (10.9 to 15.3) | 9.3 (7.3 to 10.4) |
Time from randomisation until death due to any cause.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 19.3 (16.7 to 21.8) | 19.6 (14.1 to 24.2) |
Number of responders according to blinded independent central review (BICR) assessment. Per Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR.
| Participants | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) | 100 | 19 |
Change from baseline in global health status/quality of life (QoL) score assessed using a mixed model for repeated measures (MMRM) analysis, including all post-baseline global health status/QoL scores up to the latest scheduled visit where at least 20 patients on each treatment arm have a score. Global health status/QoL score is on a scale from 0 to 100. A higher score represents an improved health status/QoL.
| Score on a scale | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30) | 3.9 (1.5 to 6.3) | -3.6 (-8.0 to 0.8) |
Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Assessed in patients with a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm | 7.4 (5.7 to 8.3) | 4.2 (2.8 to 4.3) |
Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Time to First Subsequent Cancer Therapy or Death (TFST) | 9.4 (8.3 to 10.6) | 4.2 (3.3 to 5.2) |
Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Time to Second Subsequent Cancer Therapy or Death (TSST) | 14.3 (12.2 to 15.5) | 10.5 (8.4 to 11.3) |
Time from randomisation until death due to any cause.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Overall Survival (OS) at Final OS | 19.3 (17.2 to 21.6) | 17.1 (13.9 to 21.9) |
Time from randomisation until death due to any cause.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Overall Survival (OS) at Extended OS | 19.3 (17.2 to 21.6) | 17.1 (13.9 to 21.9) |
Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Time to First Subsequent Cancer Therapy or Death (TFST) at Extended OS | 9.4 (8.3 to 10.6) | 4.3 (3.4 to 5.4) |
Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.
| Months | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS | 14.3 (12.3 to 15.7) | 10.5 (8.5 to 11.3) |
Collected over Adverse events and serious adverse events were collected throughout the study until study completion (up to a maximum of 30 months). They are reported from date of first dose of study treatment until the earliest of 30 days after last dose of study treatment and data cut-off.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 300 mg bd | 159/205 (77.6%) | 37/205 (18%) | 196/205 (95.6%) |
| Chemotherapy | 73/97 (75.3%) | 15/91 (16.5%) | 85/91 (93.4%) |
| Event | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/205 | 2/91 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/205 | 2/91 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/205 | 0/91 |
| PyrexiaGeneral disorders | 3/205 | 0/91 |
| Febrile bone marrow aplasiaBlood and lymphatic system disorders | 0/205 | 1/91 |
| NeutropeniaBlood and lymphatic system disorders | 0/205 | 1/91 |
| AscitesGastrointestinal disorders | 0/205 | 1/91 |
| DiarrhoeaGastrointestinal disorders | 0/205 | 1/91 |
| NauseaGastrointestinal disorders | 0/205 | 1/91 |
| VomitingGastrointestinal disorders | 0/205 | 1/91 |
| Event | Olaparib 300 mg bd | Chemotherapy |
|---|---|---|
| NauseaGastrointestinal disorders | 119/205 | 31/91 |
| AnaemiaBlood and lymphatic system disorders | 76/205 | 21/91 |
| VomitingGastrointestinal disorders | 66/205 | 13/91 |
| FatigueGeneral disorders | 61/205 | 22/91 |
| NeutropeniaBlood and lymphatic system disorders | 37/205 | 27/91 |
| DiarrhoeaGastrointestinal disorders | 42/205 | 19/91 |
| White blood cell count decreasedInvestigations | 33/205 | 19/91 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 1/205 | 19/91 |
| HeadacheNervous system disorders | 41/205 | 14/91 |
| Neutrophil count decreasedInvestigations | 21/205 | 17/91 |
Full analysis set consisting of all randomized patients.
| Age, Continuous(Years) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| Age (years) | 44 (22 to 76) | 45 (24 to 68) | 44 (22 to 76) |
| Age, Customized(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| <50 | 138 | 63 | 201 |
| >=50-<65 | 56 | 30 | 86 |
| >=65 | 11 | 4 | 15 |
| Sex: Female, Male(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| Female | 200 | 95 | 295 |
| Male | 5 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 66 | 28 | 94 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 134 | 63 | 197 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| Global — BULGARIA | 4 | 4 | 8 |
| Global — CHINA | 32 | 9 | 41 |
| Global — CZECH REPUBLIC | 11 | 1 | 12 |
| Global — FRANCE | 5 | 4 | 9 |
| Global — HUNGARY | 10 | 0 | 10 |
| Global — ITALY | 17 | 7 | 24 |
| Global — JAPAN | 15 | 9 | 24 |
| Global — KOREA | 11 | 9 | 20 |
| Global — MEXICO | 1 | 4 | 5 |
| Global — PERU | 3 | 1 | 4 |
| Global — POLAND | 10 | 5 | 15 |
| Global — ROMANIA | 1 | 1 | 2 |
| Global — RUSSIAN FEDERATION | 10 | 5 | 15 |
| Global — SPAIN | 7 | 6 | 13 |
| Global — SWITZERLAND | 6 | 2 | 8 |
| Global — TAIWAN | 1 | 1 | 2 |
| Global — TURKEY | 8 | 6 | 14 |
| Global — UNITED KINGDOM | 8 | 4 | 12 |
| Global — UNITED STATES | 45 | 19 | 64 |
| Receptor status(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| ER and/or PgR positive | 103 | 49 | 152 |
| ER and PgR negative | 102 | 48 | 150 |
| Received prior chemotherapy for metastatic breast cancer(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| Yes | 146 | 69 | 215 |
| No | 59 | 28 | 87 |
| Received prior platinum for breast cancer(Participants) | Olaparib 300 mg bd | Chemotherapy | Total |
|---|---|---|---|
| Yes | 60 | 26 | 86 |
| No | 145 | 71 | 216 |
Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2014 to primary completion in Dec 2016, 32 months.
Results were first posted in Dec 2017, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib